DOGS VACCINES MARKET Size and trends

Dogs Vaccines Market Size and Trends

The Global Dogs Vaccines Market is estimated to be valued at USD 2.21 Bn in 2025 and is expected to reach USD 3.52 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.

Key Takeaways of the Dogs Vaccines Market:

• By type of vaccine, the attenuated live vaccines segment is estimated to contribute the highest market share of 32.1% in 2025.
• By application, the canine parvovirus segment is estimated to contribute the highest market share of 25.6% in 2025.
• By route of administration, the injectable vaccines segment is estimated to contribute the highest market share of 32.4% in 2025.
• North America is projected to top the global market with 32.3% share, followed by Asia Pacific with 27.7% share in 2025.

Market Overview:

Increasing awareness among pet owners regarding routine vaccination is driving the market growth. Various technological advancements in vaccine development have further fueled the market growth. Increasing global adoption of pets, particularly dogs, driven by rising disposable income and lifestyle changes, especially in developing nations is leading to high demand for dog vaccines. As pet ownership grows, spending on pet healthcare, including vaccines, has significantly increased. This trend is further supported by the launch of region-specific vaccines tailored to address diseases prevalent in particular areas, boosting customer trust and acceptance. Overall, the trend highlights the growing importance of pets in households and the corresponding demand for high-quality healthcare products to ensure their well-being.

To learn more about this report, Request sample copy

Key Developments:

• On January 3, 2025, the Texas Department of State Health Services (DSHS) launched the 2025 oral rabies vaccination program, expanding bait drops to West Texas and areas near New Mexico to combat a new Arizona fox rabies variant. Since 1995, the program has successfully eliminated two rabies variants in Texas, U.S. reducing cases and preventing human infections.
• In June 2024, Merck & Co., Inc., a global healthcare leader, introduced the NOBIVAC NXT Rabies portfolio in Canada, including NOBIVAC NXT Canine-3 Rabies and NOBIVAC NXT Feline-3 Rabies, reaffirming its dedication to rabies prevention.
• In March 2024, Zendal Group, a biopharmaceutical company, launched a recombinant vaccine, developed in collaboration with CSIC, Spanish National Research Council, a leading public research institution to combat canine leishmaniasis, a parasitic disease that can cause skin ulcers and severe inflammation of the liver and spleen.
• In January 2022, Boehringer Ingelheim, a global pharmaceutical company, partnered with MabGenesis, a biopharmaceutical company, to advance the discovery of novel monoclonal antibodies for use in canines
• In November 2021, Ceva, a veterinary pharmaceutical company, invested in its European vaccine production capabilities by establishing a cryogenic storage facility in Monor, Hungary to address the rising demand for vaccines

Top Strategies Followed by Global Dogs Vaccines Market Players:

• Established Players: Leading companies in the dogs vaccines market are heavily investing in R&D to innovate and enhance vaccine efficacy
  • For instance, Zoetis Inc. received U.S. FDA approval for Librela (bedinvetmab injectable) in May 2023, marking it as the first monthly anti-NGF monoclonal antibody treatment for canine osteoarthritis pain. Collaborations are pivotal for market expansion and technological advancements.
  • In January 2021, Boehringer Ingelheim partnered with PetMedix to develop novel antibody therapeutics for companion animals, leveraging PetMedix's proprietary Ky9 platform
• Mid-Level Players: Mid-level companies are focusing on delivering quality vaccines at competitive prices to cater to price-sensitive consumers. To enhance technological capabilities and market presence, mid-level players are engaging in partnerships.
  • For instance, Touchlight, a biotechnology company, entered a non-exclusive licensing agreement with GSK in July 2024 to utilize its Doggybone DNA (dbDNA) technology for mRNA-based product development.
• Small-Scale Players: Small-scale players often specialize in niche markets, offering unique vaccine formulations tailored for specific breeds or conditions. A notable example is Canine Health, which focuses on vaccines for rare diseases affecting specific dog breeds. Additionally, technology adoption is increasingly common; companies like VetInnovate are utilizing AI-driven diagnostics to improve vaccine efficacy and monitoring processes

Emerging Startups - Dogs Vaccines Industry Ecosystem:

• Innovative Technologies: Startups are emerging with groundbreaking technologies such as smart sensors and AI solutions. For example, DogTech, a startup, is developing an AI-driven platform that analyzes vaccination data and predicts canine health trends, potentially transforming market dynamics. Such innovations could lead to more precise vaccination schedules and improved health outcomes for dogs.
• Several startups, like GreenPaw, focus on eco-friendly vaccine products, using recycled materials for packaging. Their commitment to sustainability aims to reduce the environmental footprint of the veterinary industry.
• Sustainable Solutions: Startups like BioCina focus on upcycling food waste into sustainable packaging for vaccines. Their eco-friendly approach reduces environmental footprint. Another startup, Resson, creates biodegradable vaccine delivery devices from plant-based polymers.
• Market Contribution: Emerging companies address specific needs like thermo-stable vaccines for tropical regions or allergy vaccines for atopic dogs. This helps gain first-mover advantages in untapped markets. Startups often partner with research institutes and large manufacturers by offering novel solutions.